Clinical data | |
---|---|
Other names | PF-06741086 |
ATC code |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG |
Marstacimab is an experimental monoclonal antibody intended for the treatment of hemophilia A and B.[1] It is being developed by Pfizer.[2]
Hympavzi EPAR
was invoked but never defined (see the help page).